KannaLife Sciences was mentioned in an article by Capital New York written by Laura Nahmias about the recent surge for in business from the legalization of medical marijuana, and their plan for acquiring state licenses.
“Manufacturers most likely to succeed must demonstrate they’ve thought out every detail of their production plan, from security, to support from local lawmakers, to plans for how they’ll transport the plants from manufacturers to dispensaries.
“These applications are going to have to be very comprehensive in their approach to address all the requirements,” said Patrick McCarthy, a lobbyist for Mercury Public Affairs, which represents multiple medical marijuana interests including biopharmaceutical company KannaLife Sciences, Inc. ”
